Beeline Medicines
Beeline Medicines is a Boston-based, clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases, with a five-program pipeline (including lead asset afimetoran for lupus) licensed from Bristol Myers Squibb and funded by a $300M Bain Capital-led Series A.
- Company typePrivate
- Founded2025
- HeadquartersStamford, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Beeline Medicines does
Beeline Medicines is a clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases. Founded in July 2025 through a partnership between Bristol Myers Squibb and Bain Capital Life Sciences, the company officially launched from stealth in April 2026 with a $300 million Series A financing led by Bain Capital Life Sciences with participation from CPP Investments. It is headquartered in Boston, Massachusetts with an additional operational presence in Stamford, Connecticut, and operates with 11-50 employees. The company's pipeline consists of five immunology programs licensed from Bristol Myers Squibb: afimetoran (an oral TLR7/8 inhibitor in Phase 2 for systemic lupus erythematosus with FDA Fast Track designation), BLN-326 (a long-acting IL-2-CD25 fusion protein in Phase 1b for atopic dermatitis and lupus), lomedeucitinib (a next-generation allosteric TYK2 inhibitor that completed a Phase 2 psoriasis trial), BLN-481 (a selective anti-IL-18Rb antibody with a planned Phase 1 study), and BLN-498 (a myeloid-selective IL-10 therapeutic in preclinical development).
The company's underlying technology centers on mechanistically-informed precision immunology, using small molecule inhibitors and biologic therapeutics to target validated upstream drivers of immune dysregulation (endosomal TLRs, TYK2 signaling, IL-18 receptor beta) and to rebalance Treg/effector and pro-/anti-inflammatory axes, with the goal of restoring immune homeostasis rather than broadly suppressing immunity. Several assets are positioned as first-in-class or best-in-class within their respective mechanism classes, and the oral, once-daily dosing of the small molecule programs is highlighted as a differentiator.
Beeline Medicines is pre-revenue and has not disclosed pricing for future commercial products. Its business model anticipates revenue generation through the future commercialization of approved therapeutics via pharmaceutical wholesale and specialty pharmacy distribution channels, targeting rheumatologists, dermatologists, and other specialists treating patients with lupus, atopic dermatitis, psoriasis, and other immune-mediated conditions. Until regulatory approval, the company is funded by its $300M Series A and operates as a clinical development organization with enterprise go-to-market characteristics rather than a commercial sales operation.
Beeline Medicines firmographics
Firmographics- Name
- Beeline Medicines
- Legal name
- Beeline Medicines Corporation
- Website
- https://beelinemedicines.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Beeline Medicines is a Boston-based, clinical-stage biotechnology company developing precision immunology therapies for autoimmune and inflammatory diseases, with a five-program pipeline (including lead asset afimetoran for lupus) licensed from Bristol Myers Squibb and funded by a $300M Bain Capital-led Series A.
- Ownership category
- akta.pro rank
Beeline Medicines industry classification
Industry- Product category
- Autoimmune and Inflammatory Disease Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro industry
- Immunology & Autoimmune Specialty Pharmaceuticals
Keywords
Where Beeline Medicines is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Beeline Medicines business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical product sales: Pre-revenue clinical-stage biotech company. The company is developing a pipeline of five immunology programs licensed from Bristol Myers Squibb. Revenue will be generated through commercialization of approved therapeutics for autoimmune and inflammatory diseases once clinical development is completed and regulatory approvals are obtained.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Beeline Medicines product offering
Product offeringCore offering
Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies — small molecule inhibitors and biologic therapeutics — licensed from Bristol Myers Squibb. The portfolio targets validated pathways of immune dysfunction in autoimmune and inflammatory diseases, with lead program afimetoran (TLR7/8 inhibitor) advancing in Phase 2 for systemic lupus erythematosus under FDA Fast Track designation.
Product overview
Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies licensed from Bristol Myers Squibb for autoimmune and inflammatory diseases. The portfolio includes Afimetoran (oral TLR7/8 inhibitor for lupus), BLN-326 (IL-2-CD25 fusion protein for atopic dermatitis/lupus), Lomedeucitinib (TYK2 inhibitor), BLN-481 (anti-IL-18Rb antibody), and BLN-498 (myeloid-selective IL-10). The company's mechanistically-informed approach targets underlying causes of immune-mediated diseases with the goal of restoring immune balance and delivering transformative impact for patients.
Differentiator
Problem solved
Functional benefit
Products and services
- Afimetoran Selective, oral, once-daily equipotent small molecule inhibitor of TLR7 and TLR8 for lupus treatment, blocking endosomal immune receptors that drive type I interferon production, pro-inflammatory cytokine release, and downstream autoantibody generation. Lead indication is systemic lupus erythematosus (SLE).
- BLN-326 (formerly BMS-986326) Novel, long-acting IL-2-CD25 fusion protein biologic designed to slowly release IL-2 and selectively expand FOXP3+ regulatory T cells for inflammatory diseases. In development for atopic dermatitis and lupus.
- Lomedeucitinib (formerly BMS-986322) Oral, next-generation, allosteric small molecule TYK2 inhibitor with enhanced selectivity and no functional activity against JAK1/2/3. Demonstrated compelling clinical activity in a Phase 2 psoriasis trial with planned development in multiple autoimmune and inflammatory conditions.
- BLN-481 (formerly BMS-986481) First and only therapeutic antibody designed to selectively antagonize IL-18 receptor beta (IL-18Rb), providing a receptor-specific approach to blocking IL-18-driven inflammation while preserving homeostatic functions. In preclinical/early clinical development.
- BLN-498 (formerly BMS-986498) Potentially first-in-class myeloid-selective IL-10 therapeutic engineered to harness anti-inflammatory and tolerance-promoting effects while avoiding T-cell-driven IFN-gamma activation and hematologic toxicities seen with non-selective IL-10 therapies. In preclinical development.
Quantifiable outcome
- Phase 2 trial completion expected in second half of 2026 for afimetoran in SLE
- +1 more outcomes
Companies that use Beeline Medicines
Customer profileSegments2 records
Ideal customer profiles3 records
Beeline Medicines technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Beeline Medicines partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bristol Myers SquibbcoreBeeline Medicines licensed five immunology and inflammation drug candidates from Bristol Myers Squibb as the foundation of its pipeline. The programs include afimetoran (TLR7/8 inhibitor), BLN-326 (IL-2-CD25 fusion protein), lomedeucitinib (TYK2 inhibitor), BLN-481 (Anti-IL-18Rb antibody), and BLN-498 (Myeloid-selective IL-10). The company was originally formed in July 2025 through this partnership. Bristol Myers Squibb's Chief Research Officer, Dr. Robert Plenge, serves on Beeline Medicines' Board of Directors.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
Beeline Medicines competitors and assessment
Company assessmentBroad incumbents
- Eli Lilly: Large pharma with Olumiant (baricitinib) approved in lupus and other autoimmune indications and a deep immunology pipeline; comparable broad incumbent setting competitive benchmarks in Beeline's target indications.
- Sanofi: Global pharma co-developing Dupixent (dupilumab) with Regeneron, the dominant atopic dermatitis therapy; directly relevant incumbent competitor to BLN-326 in atopic dermatitis and to Beeline's broader IL-pathway programs.
- AbbVie: Large immunology incumbent with leading franchises Skyrizi and Rinvoq across psoriatic and rheumatologic diseases; comparable broad incumbent defining the standard-of-care landscape Beeline's TYK2 and IL-2 programs must compete against.
- Bristol Myers Squibb: Large pharmaceutical company that originated Beeline's pipeline and markets Sotyktu (TYK2 inhibitor) and Saphnelo (lupus); key licensor, board participant, and the most direct incumbent competitor in Beeline's target indications.
Direct peers
- Argenx: Late-stage immunology biotech with approved FcRn antagonist Vyvgart (efgartigimod) for autoimmune indications; directly comparable as a focused, clinical-stage-to-commercial immunology company executing a multi-indication precision-immunology strategy.
- MoonLake Immunotherapeutics: Clinical-stage immunology company developing nanobody-based therapies for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis; comparable as a focused, asset-centric inflammation biotech pursuing differentiated biologics.
- Alpine Immune Sciences: Pre-commercial immunology biotech developing engineered protein therapies for autoimmune and inflammatory diseases (acquired by Vertex for ~$4.9B in 2024); directly comparable precision-immunology peer with a similar small-molecule-and-biologic pipeline profile.
- Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications; comparable as a platform-based immunology company advancing novel mechanisms into autoimmune disease trials.
- AnaptysBio: Clinical-stage immunology-focused biotech developing antibodies for inflammatory and autoimmune diseases; comparable peer pursuing similar mechanism-driven, indication-targeted development in rheumatology and dermatology.
Emerging players
- Vertex Pharmaceuticals: Mid-to-late-stage biotech that entered autoimmune disease via the Alpine Immune Sciences acquisition and is advancing selective immunology assets; comparable as a recently expanded immunology platform with a similar precision-mechanism thesis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Beeline Medicines social profiles
Digital presenceBeeline Medicines financial estimates
Financial estimateRevenue estimate
Valuation estimate
Beeline Medicines leadership team
Management profileNumber of profiles
Profiles11 records
Beeline Medicines funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Beeline Medicines M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Beeline Medicines
What does Beeline Medicines do?
Beeline Medicines is a clinical-stage biotechnology company developing a pipeline of five precision immunology therapies — small molecule inhibitors and biologic therapeutics — licensed from Bristol Myers Squibb. The portfolio targets validated pathways of immune dysfunction in autoimmune and inflammatory diseases, with lead program afimetoran (TLR7/8 inhibitor) advancing in Phase 2 for systemic lupus erythematosus under FDA Fast Track designation.
Is Beeline Medicines a public or private company?
Beeline Medicines is a private company. It is classified as venture growth investor backed and is currently operating.
When was Beeline Medicines founded?
Beeline Medicines was founded in 2025. It employs 51 to 100 people.
Where is Beeline Medicines based?
Beeline Medicines is headquartered in Stamford, United States, in the North America region.
How does Beeline Medicines make money?
One revenue line is on record: pharmaceutical product sales.
Who are Beeline Medicines's main competitors?
Broad incumbents on record are Eli Lilly, Sanofi, AbbVie and Bristol Myers Squibb. Direct peers are Argenx, MoonLake Immunotherapeutics, Alpine Immune Sciences, Kymera Therapeutics and AnaptysBio. Vertex Pharmaceuticals is listed as an emerging player.
Does Beeline Medicines have an API?
No public API is recorded for Beeline Medicines.
What industry is Beeline Medicines in?
Beeline Medicines's product category is Autoimmune and Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.